Skip to content

Berman Center for Outcomes & Clinical Research

Better Care through Better Research

Since its founding in 1966 by Dr. Reuben Berman, a pioneer in cardiovascular clinical research, The Berman Center for Outcomes and Clinical Research, in Minneapolis, MN, has achieved an international reputation for conducting clinical research. The Berman Center is known for studies in NIH-funded cardiovascular research, diabetes (ACCORD) and women’s health issues (WHI) -- under Dr. Richard Grimm -- and more recently for work on dementia and aging, chronic kidney disease (CKD) and cognitive impairment, under Berman Center Medical Director Dr. Anne Murray. We serve as the North Star Node for multiple addiction medicine trials (Dr. Gavin Bart), and many other CKD and dialysis disease studies (Dr. Kirsten Johansen). Over the past 10 years the volume of studies has grown substantially

The Berman Center supports the research mission of Hennepin Health Research Institute (HHRI) and Hennepin Health System (HHS), by serving as its primary clinical site for over 100 clinical trials and observational studies, and national coordinating center for multiple large trials. The Berman Center supports the research mission of Hennepin Health Research Institute (HHRI, founded in 1952), the third largest nonprofit medical research institution in the state of Minnesota. HHRI operates within Hennepin Healthcare, an integrated system of care that includes a nationally recognized Level I Adult and Pediatric Trauma Center, a 484-bed academic hospital, and primary care clinics. Hennepin Healthcare is the largest public hospital in Minnesota. The system is operated by Hennepin Healthcare System, a subsidiary corporation of Hennepin County.

The Berman Center provides comprehensive research services support.

Our experienced staff assists with all stages of the clinical research process, including our team of principal investigators, project managers, study coordinators, research assistants, and administrative support.

  • Refine research questions
  • Study recruitment
  • Grant writing
  • Screen, schedule and consent study participants
  • IRB and regulatory management
  • Laboratory draws, processing and shipment
  • Design study protocols
  • Multi-site study monitoring
  • Project management
  • Outpatient clinical interventions
  • Study budget development and monitoring
  • Publication support
  • Design data collection systems

We are positioned to continue our growth to serve more investigators who lead research aligned with rigorous best practices and findings that translate to improved public health; especially for studies focused on our diverse patient population. However, we cannot continue this growth without new financial resources, and have approached several potential donors to sustain the Berman Center’s tremendous success.

The Berman Center is located on the campus of Hennepin Healthcare, on the 4th floor of the Parkside Professional Center on the eastern edge of downtown Minneapolis. The Parkside Professional Center is across the street from the Hennepin Healthcare Clinic & Specialty Center, and the convenient Parkside Parking Ramp occupies its lower floors.

The office space includes administrative and medical offices, fully equipped procedure/examination rooms, laboratory phlebotomy station, a reception area for central patient coordination, a secure medical records room, recruitment stations, patient education wing, support staff facilities, and a conference room. The laboratory is equipped for drawing, processing, storing and shipping specimens for multiple study protocols. All clinical and support staff have either private or shared offices that overlook Elliot Park green space.

Our Investigators

Anne Murray, MD, MSc
Gavin Bart, MD, PhD

Active Studies


  • ASPREE (ASPirin in Reducing Events in the Elderly). Aspirin trial and ASPREE-XT observational follow on study. Dr. Anne Murray, Co-PI. U.S. coordinating center for landmark NIA study with Monash University in Melbourne, Australia in over 19,000 healthy older participants for 13 years, with over $100 million in NIH funding, and over 200 publications regarding dementia, disability, frailty, genomics, and cancer outcomes.
  • HATS (Healthy Aging in the Senior Years). Dr. Anne Murray, Co-PI, to explore reasons for the two-fold risk of dementia in older U.S. Blacks and to measure cardiovascular risk factors for dementia in 300 older Black community residents of the Twin Cities in collaboration with Mayo Clinic Co-PI Dr. David Knopman and community engagement partners Hue-MAN and the LinC.
  • Sex-Specific Risk Factors and Trajectories of Blood Biomarkers for ADRD. Anne Murray.

Addiction Medicine: Dr. Gavin Bart, PI, leads the National Institute on Drug Abuse (NIDA) Center for Clinical Trials Network (CCTN) Northstar Node for multiple studies.

  • ADAPT Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder
  • EXHIT-ENTRE Exemplar Hospital Initiation Trial to Enhance Treatment Engagement
  • NORTHSTAR Clinical Trials Network
    • COMPUTE 2.0 CTN-0095: Clinic-Randomized Trial of Clinical Decision Support for Opioid Use Disorders
      in Medical Settings
    • CTN-0095-A-1: Suicide Prediction and Prevention for People at Risk for Opioid Use Disorder
    • CTN-0095-A-2: Reducing Stigma Toward People with Opioid Use Disorder Among Primary Care Clinicians
    • CTN-0096: Culturally Centered MAT for OUD Implementation Facilitation for Primary Care and Addiction Treatment Programs Serving American Indian/Alaska Natives
    • ED-INNOVATION CTN-0099: Emergency Department-INitiated bupreNOrphine and VAlidaTIOn Network
    • CURB-2 CTN-0109: Randomized, Placebo-controlled Trial of Injectable Naltrexone and Monthly Injectable Buprenorphine for Cocaine Use Disorder
    • CTN-0123: Facebook Intervention for Preventing Opioid Relapse among American Indian Women
    • CTN-0127: Engaging African American Faith-Based Leaders in a Substance Use Learning Collaborative
    • MOUD CTN-0131: Office-Based Methadone versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder —A Pragmatic Hybrid Effectiveness/Implementation Trial


  • HOPE Hemodialysis Opioid and Pain Reduction Effort. Dr. Kirsten Johansen.
  • REACH Research and Evaluation Commercialization Hubs REACH DART. Kirsten Johansen.
  • IDMS Intradialytic Myocardial Stunning

Infectious Disease

  • STRIVE Strategies and Treatments for Respiratory Infections and Viral Emergencies. Dr. Jason Baker. COVID U.S./Mexico International Coordinating Center - network support. To investigate drugs and treatment strategies for adults in the hospital with respiratory or lung infection.
  • OTAC Covid-19 outpatient observational study

Amyotrophic Lateral Sclerosis (ALS)

  • PHOENIX – Phase III Trial of AMX0035
  • CREATE/CAPTURE. DNA repository.


Join a research study, help others, and learn more about your own health.  Please browse through the sidebar to see which of our enrolling studies interests you.

For more information on any of our current studies, please call 612-873-6900 or email

Previous Studies

Our Collaborators

Principal Investigators for multi-site trials for which the Berman Center has served either as a regional coordinator or as a clinical site:

Colin B, Baignet, BM * University of Oxford, Oxford, United Kingdom * SHARP, Study of Heart and Renal Protection

Merit Cudkowicz, MD * Massachusetts General Hospital/Harvard Medical School, Boston, MA * Celebrex in ALS

Robert Byington, PhD * Wake Forest School of Medicine, Winston-Salem, NC * ACCORD, Action to Control Cardiovascular Risks in Diabetes

John McNeil, PhD, MSc * Monash University, Melbourne, Australia * ASPREE, ASPirin in Reducing Events in the Elderly

Charles H. Hennekens, MD, DrPh * Mount Sinai Medical Center * TACT, Trial to Assess Chelation Therapy (Co-principal Investigator)

Gervasio A. Lamas, MD * Mount Sinai Medical Center * TACT, Trial to Assess Chelation Therapy (Co-principal Investigator)

Oscar Benavente, MD * University of Texas Health Science Center, San Antonio, TX *
SPS3, Secondary Prevention of Small Subcortical Strokes

Martin Landray, BM * University of Oxford, Oxford, United Kingdom * SHARP, Study of Heart and Renal Protection

Jeffery Probstfield, MD * University of Washington School of Medicine * ORIGIN, Outcome Reduction with Initial Glargine Intervention (Principal Investigator for U.S. Regional Coordinating Center)

Eric Sorenson, MD * Mayo Clinic, Rochester, MN * IGF-I (Myotrophin) in ALS

Hertzel Gerstein, MD * Professor of Medicine and Chief of Division of Endocrinology
McMaster University Faculty of Health Sciences
Hamilton, Ontario, Canada * ORIGIN, Outcome Reduction with Initial Glargine Intervention (Co-principal Investigator) * DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (Co-principal Investigator)

Salim Yusuf, MD * Professor of Medicine and Chief of Division of Cardiology
McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada
ORIGIN, Outcome Reduction with Initial Glargine Intervention (Co-principal Investigator)
DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone
Medication (Co-principal Investigator) * ONTARGET/TRANSCEND
OnTarget: Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial: A large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events Transcend: Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease

The Berman Center has established high-quality, primary and specialty care research networks that extend across the globe. The networks include cardiologists, neurologists, endocrinologists, nephrologists, hypertension specialists and internists covering a wide range of chronic disease disciplines. Additionally, these networks include many experienced clinical research associates trained in ICH-GCP procedures. The networks include centers in established markets such as North America, Western Europe and Australia. Utilizing in-depth feasibility studies, Berman can quickly identify appropriate sites that have a commitment to scientific excellence, have a history of delivery to timelines, and quality of operations.


To Contact Us, Call


Mailing Address:
701 Park Ave, PP4.440
Minneapolis MN 55415

Physical Address:
825 S 8th St, Suite 440
Minneapolis MN 55404

input search string and hit enter